Main content

    Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at


    Active Trials


    Title: A Phase I/ Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
    Description: This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic).
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with histopathologically confirmed sarcoma of one of the subtypes and who have measurable locally advanced or metastatic disease
    Status: Contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: about Study Alliance A091304

    • updated December 2016

    Back to top